About Anaxa

Anaxa is an early-stage biotech start-up dedicated to improving the diagnosis of sarcoidosis and other autoimmune diseases. Our mission is to develop a reliable and accessible diagnostic tool based on the detection of disease-specific autoantibodies.

Current diagnostic methods for sarcoidosis are often invasive, time-consuming, and inconclusive. By leveraging advances in immunology and biomarker research, Anaxa aims to offer a non-invasive, antibody-based blood test that can accelerate diagnosis, reduce patient burden, and support earlier treatment decisions.

Anaxa is a spin-off from the Karolinska Institutet, one of the world's leading medical research institutions. Our work builds on cutting-edge research conducted at KI, and we maintain close ties to both clinical and academic experts in the fields of immunology, pulmonology, and diagnostics.